Using Probate’s data
As of the edition of 20 October 2026: what you may do with the public pages and the data behind them, how to credit it, and the terms of the sources it is built from.
What this covers
The public pages of probate.bio (the pages for drugs, companies, targets and years of US protection, and the method, editions and worked-example pages) and the dataset the method page describes: a list of human protein targets, each paired with the companies most likely to want a new molecule for it. The signed-in product at app.probate.bio is provided under the plan an organisation takes (see the plans) and is not covered here.
The public pages are a sample on purpose. They show the facts of one drug, company or target, true counts, and the route label of the first three rows. Which other companies, how strongly and on what evidence is the paid product. There is no free account and no free plan.
What you may do
- Read, print and share the pages, and link to them.
- Cite and quote individual facts, such as a drug’s status, the year its US protection ends or how many companies are on a route, in articles, reports, presentations, research and your own documents, with the credit line below and a link to the page the fact came from.
- Let search engines index the pages as our robots file allows.
What needs our written permission
- Copying the pages in bulk, or reading them systematically with a script, crawler or other automated tool.
- Republishing the compilation, or the routes, rankings and scores built from it, as a dataset, list, table or feed, or inside a product or service.
- Using the pages or the data to build or fill a competing database.
- Presenting Probate’s analysis as your own, or suggesting that we endorse you.
Exports, saved lists and the full data are part of the paid plans. For any other use, write to [email protected].
How to credit
Source: Probate (probate.bio), edition of 20 October 2026
Use the edition date shown at the top of the page the fact came from, and link to that page. Probate’s pages bring together facts from the public sources below. A fact quoted from a page still comes from its source, so where a source asks for a credit, give that credit as well (last column of the table).
Sources and their terms
Probate adds the selection, the links between records, the names, the wording, and the routes and rankings. The facts underneath are taken from public registers and databases and stay under those sources’ terms. Nothing on this page limits what a source’s own terms let you do with that source’s material, and where a source’s terms require it, the part of the data that comes from that source is available under those terms. The terms below are as each source states them, read on 23 October 2026; follow the link in each row for the full text.
| Source | What Probate takes from it | Its terms | Credit line |
|---|---|---|---|
| Trials | |||
| ClinicalTrials.gov (US National Library of Medicine) | Trial counts, phases, statuses, sponsors, stated stop reasons, results; the date a drug went quiet or stopped. | Free to use. Credit ClinicalTrials.gov, show the date the data were processed, and say what was changed. Some records may carry a third party's copyright. | Source: ClinicalTrials.gov (data as of the edition date), modified by Probate. |
| MeSH disease terms (US National Library of Medicine) | The therapeutic area each trial, drug and target is placed in. | Credit the National Library of Medicine, and do not suggest it endorses the product. | Courtesy of the U.S. National Library of Medicine. |
| US approvals and protection | |||
| FDA Orange Book, Purple Book, Drugs@FDA and orphan designations | US approvals and their holders, patents and exclusivities (shown as a year), licensed biologics, orphan designations. | FDA says its website content is in the public domain and may be reused without permission; credit is appreciated, not required. | Source: US Food and Drug Administration. |
| Approvals outside the US | |||
| European Medicines Agency (medicines register, PRIME list) | EU approvals, refusals and withdrawals, and priority-medicine designations. | May be reproduced for commercial and non-commercial purposes if EMA is named as the source in each copy. Content supplied by third parties is excluded. | Source: European Medicines Agency. |
| Japan: Pharmaceuticals and Medical Devices Agency (PMDA) | New drugs approved in Japan, with the applicant and the approval date. | Public Data License 1.0: cite the source; if the content is edited, say so, and do not present it as made by the agency. | Source: Pharmaceuticals and Medical Devices Agency (PMDA) website, edited by Probate. |
| Canada: Health Canada Drug Product Database | Products authorised in Canada, with the company and the date. | Health Canada's own terms allow non-commercial reproduction with a credit and ask for written permission before commercial redistribution. The national open-data portal lists the same database under the Open Government Licence - Canada. | Source: Health Canada, Drug Product Database. |
| Switzerland: Swissmedic open government data | Medicines authorised in Switzerland, with the licence holder and the first authorisation date. | Open use, including commercial use; a credit is recommended. | Source: Swissmedic. |
| France: Base de données publique des médicaments | Medicines authorised in France, with the holder and the date. | Open licence (Etalab): the source must be named, the data must not be altered or have their meaning distorted, and the credit does not make the reuse official. | Source: Base de données publique des médicaments (ANSM, HAS, UNCAM). |
| Spain: AEMPS medicines information centre (CIMA) | Medicines authorised in Spain, with the holder and the date. | May be reproduced if the origin is named; the date of the last update of the material reused must be stated. | Source: AEMPS (CIMA), updated at the edition date. |
| Brazil: Anvisa open data | Medicines registered in Brazil, with the holder and the date. | Anvisa publishes its open-data content under Creative Commons Attribution-NoDerivatives 3.0. | Source: Anvisa (Brazil), Creative Commons Attribution-NoDerivatives 3.0. |
| Drugs, targets and proteins | |||
| ChEMBL (EMBL-EBI) | Drug identity, kind and names; which protein a drug acts on. | Creative Commons Attribution-ShareAlike 3.0: credit ChEMBL, and release material built from it under the same terms. | Source: ChEMBL (EMBL-EBI), CC BY-SA 3.0. |
| DrugCentral | Drug names and identifiers, which protein a drug acts on, and approval records. | Creative Commons Attribution-ShareAlike 4.0: credit DrugCentral, and release material built from it under the same terms. | Source: DrugCentral, CC BY-SA 4.0. |
| IUPHAR/BPS Guide to PHARMACOLOGY | The main target of a drug, where no other source names one. | The database is under the Open Database Licence and its contents under Creative Commons Attribution-ShareAlike 4.0. | Source: IUPHAR/BPS Guide to PHARMACOLOGY, CC BY-SA 4.0. |
| UniProt | Protein names, and where a protein sits in the cell. | Creative Commons Attribution 4.0: credit UniProt. | Source: UniProt, CC BY 4.0. |
| Open Targets Platform | Target names, drugs withdrawn from the market, and its copy of UniProt's cell locations. | Creative Commons CC0 1.0 for the platform. It carries data from other sources, each listed on its page with that source's own licence. | Source: Open Targets Platform (CC0). |
| Pharos (NIH) | How well studied a target is. | Pharos states no licence of its own and asks users to respect the licences of the sources it draws on. | Source: Pharos (NIH NCATS). |
| HGNC (HUGO Gene Nomenclature Committee) | Approved gene symbols and names. | Creative Commons CC0: any reuse is permitted; a credit is recommended. | Source: HGNC (genenames.org). |
| RCSB Protein Data Bank | The number of solved structures of a target. | Creative Commons CC0 1.0; attributing the authors of the structures is encouraged. | Source: RCSB Protein Data Bank. |
| Companies | |||
| GLEIF (Global Legal Entity Identifier Foundation) | Matching company names to one legal entity. | Creative Commons CC0 1.0. | Source: GLEIF. |
| SEC EDGAR (US Securities and Exchange Commission) | Company names and filings, and what a company's own filings say about leaving a field. | Public filings. EDGAR's fair-access rules limit automated requests. | Source: SEC EDGAR. |
| Company announcements and public web sources | Who owns whom: acquisitions, renames, mergers and closures, with their dates. | Each source's own terms. Probate shows the fact, its date and the successor company, not the source's wording. | Source: company announcements and public records, as named in the product. |
No warranty, and not advice
The pages and the data are provided as they are, with no promise that they are complete, current or fit for any purpose. They are built from public registers that are themselves incomplete and sometimes late; the method page lists what is known to be missing. Nothing here is medical, investment or legal advice. The list is a ranked starting point for scientific review, not a verdict on any target or company. If a page is wrong, use the “Report an error” link on it.
Licensing the full data
To license the full data, the file formats, or a use this page does not cover, write to [email protected]. To see more than the public pages show, request access.